Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3843970 | 0.91 | MAPT (0.57) | KMT2AMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6478319 | 0.91 | KMT2A (0.62) | KMT2AMAPTLMNA | |
| SCHEMBL6484083 | 0.90 | KMT2A (0.62) | KMT2AMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6476553 | 0.88 | KMT2A (0.55) | KMT2AMAPTLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL6475948 | 0.86 | KMT2A (0.62) | KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL6023129 | 0.83 | BCHE (0.54) | KMT2ALMNAMEN1CA12CA1 | |
| SCHEMBL6023779 | 0.82 | KMT2A (0.51) | KMT2AALDH1A1MEN1CA12CA1 | |
| SCHEMBL6023108 | 0.81 | CA1 (0.54) | KMT2ALMNAALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6023639 | 0.81 | — | — | |
| SCHEMBL6022541 | 0.81 | CA1 (0.57) | KMT2ALMNASMN1; SMN2MEN1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641792-B1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2010-08-25 | — | — | EP | disclosed |
| EP-1641457-B1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | NYCOMED GMBH (DE) | 2009-08-05 | — | — | EP | disclosed |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1641794-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641792-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1641457-A1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | ALTANA Pharma AG (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005002579-A1 | PYRROLO-DIHYDROISOQUINOLINE DERIVATIVES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003130-A1 | NOVEL PYRROLODIHYDROISOQUINOLINES USEFUL IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005003129-A1 | PYRROLODIHYDROISOQUINOLINES AS PDE10 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | MKI67, BAD, CCAR2 | KMT2A 1763/4885MAPT 3804/4885LMNA 3565/4885 |
| US-20070105840-A1 | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors | PDE12, PDE2A, PDE5A | KMT2A 1870/4885MAPT 1795/4885LMNA 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.